Establishes the "New York regenerative medicine advancement and patient protection act" to build framework for regenerative medicine and cell-based therapies; creates patient protections and disclosure requirements; authorizes limited physician use of qualifying regenerative medicine protocols; creates a regenerative medicine registry; establishes the New York regenerative medicine innovation program.

The New York Regenerative Medicine Advancement and Patient Protection Act aims to create a structured approach to regenerative medicine and cell-based therapies in the state. It includes protections for patients, requires disclosures from healthcare providers, and allows certain physicians to use specific regenerative medicine protocols. Additionally, the bill establishes a registry for regenerative medicine practices and an innovation program to promote advancements in the field.

Supporters of the bill would highlight its potential to advance medical treatments through innovative regenerative therapies, offering hope to patients with conditions previously deemed untreatable. They would emphasize the importance of patient protections and the establishment of a regulatory framework that encourages safe and effective use of cutting-edge medical practices.

Critics may argue that the bill could lead to unregulated practices in regenerative medicine, raising concerns about the safety and efficacy of new therapies. They might express fears that the framework could prioritize innovation over patient safety, potentially exposing vulnerable patients to unproven treatments without adequate oversight.